Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
The Hailie Smartinhaler device has also been cleared for use with inhalers from other manufacturers ... the device directly to patients with asthma and COPD under a 510(k) over-the-counter ...
The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.
Individuals with early-onset COPD and rapidly progressive pre-COPD frequently have a decades-long history of impaired ...
Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disorder (COPD). The GoResp ...
Nebulizers provide a cost-effective ... This article discusses special considerations in the selection of inhaler devices for elderly patients with COPD in the outpatient setting and provides ...
For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...